ATCC 100 Years Logo Anniversary ATCC 100 Years Logo Anniversary Cart 0
  • Quick Order
  • Careers
  • Support
Immune checkpoint: Interaction between PD-1 (blue) on a T-cell and PD-L1 (red) on a cancer cell and PD-L1 inhibits T-cells

Accelerate Cancer Immunotherapy Screening with Immune Checkpoint Reporter Cells

October 31, 2024, at 12:00 PM ET
The clinical success of immune checkpoint inhibitors for treating multiple cancer types has driven interest in streamlining the development of existing and novel checkpoint inhibitor therapies. To facilitate the large-scale screening of these compounds, we generated reporter cancer cell lines that have high endogenous expression of immune checkpoint molecules (PD-L1, PD-1, and SIRPA). These reporter cell lines produce a robust, bioluminescent signal upon checkpoint blockade that can be quantified to evaluate the efficacy, potency, and dynamics of the checkpoint inhibitor. In this webinar, ATCC scientists discuss the application of these novel reporter cell lines in gamma interferon stimulation assays and immune cell co-culture assays and share insights on how these cell lines can be adopted into checkpoint reporter assay workflows.

Watch the Presentation

Presenter

Headshot of Hyeyoun Chang

Hyeyoun Chang, PhD

Scientist, ATCC

Hyeyoun Chang, PhD, is a Scientist in the Immuno-oncology group of the R&D department at ATCC. She has extensive experience in the fields of biomedical engineering and cancer biology that focuses on drug delivery, intracellular signaling, and gene therapy. Prior to joining ATCC, Dr. Chang received her PhD in biomedical engineering from Korea University of Science and Technology and completed her postdoctoral training at Dana-Farber Cancer Institute/ Harvard Medical School.